Universal Donor Expanded TGF-beta-imprinted NK Cells Clinical Trials
2 recruitingBiologic
Phase 11Phase 21Early Phase 11
Showing 1–2 of 2 trials
Recruiting
Early Phase 1
Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma
Skin Squamous Cell CarcinomaSkin Basal Cell CarcinomaSkin Nodular Basal Cell Carcinoma
Kirsten Johnson40 enrolled1 locationNCT07144384
Recruiting
Phase 1Phase 2
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
HER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8
Margaret Gatti-Mays42 enrolled1 locationNCT06026657